 MALVERN, Pa., Oct. 12, 2021 GLOBE NEWSWIRE -- Galera Therapeutics, Inc. Nasdaq: GRTX, a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Mark J. Bachleda, Pharm.D., M.B.A., as Chief Commercial Officer CCO and Jennifer Evans Stacey, Esq., as Chief Legal and Compliance Officer CLCO and Secretary. Both executives join Galera with over 25 years of leadership experience within the biopharmaceutical industry. 